Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Anastrozole + Palbociclib + Pertuzumab + Trastuzumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Anastrozole||Arimidex||Anastrozol||Aromatase Inhibitor 3||Arimidex (anastrozole) is an aromatase inhibitor, which inhibits estrogen synthesis (PMID: 29719441). Arimidex (anastrozole) is FDA approved for postmenopausal women with hormone receptor-positive early breast cancer or advanced patients who have failed tamoxifen therapy (FDA.gov).|
|Palbociclib||Ibrance||PD0332991||CDK4/6 Inhibitor 13||Ibrance (palbociclib) is a selective inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6) (PMID: 19874578). Ibrance (palbociclib) is approved in combination with an aromatase inhibitor in postmenopausal patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer, and in combination with Faslodex (fulvestrant) in patients with ER-positive, ERBB2 (HER2)-negative metastatic breast cancer (FDA.gov).|
|Pertuzumab||Perjeta||2C4 Antibody||HER2 (ERBB2) Antibody 60||Perjeta (pertuzumab) is a monoclonal antibody that binds ERBB2 (HER2) to prevent dimerization and subsequent HER signaling, thereby resulting in apoptosis and tumor growth inhibition (PMID: 15699478). Perjeta (pertuzumab) is FDA approved in combination with Herceptin (trastuzumab) and Taxotere (docetaxel) for patients with ERBB2 (HER2)-positive breast cancer and in combination with Herceptin (trastuzumab) and chemotherapy as neoadjuvant treatment for patients with ERBB2 (HER2)-positive breast cancer (FDA.gov).|
|Trastuzumab||Herceptin||Anti HER2||HER2 (ERBB2) Antibody 60||Herceptin (trastuzumab) is a monoclonal antibody, which binds ERBB2 (HER2) to induce tumor cellular cytotoxicity (PMID: 17611206). Herceptin (trastuzumab) is FDA approved for HER2-overexpressing (or amplification) breast cancer, gastric adenocarcinoma, and gastroesophageal junction adenocarcinoma (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03304080||Phase Ib/II||Anastrozole + Palbociclib + Pertuzumab + Trastuzumab||Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast||Active, not recruiting||USA||0|